Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT02113982
Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
- NCT02113982 ↗
- Completed
- Stemline Therapeutics, Inc.
- Focused
We haven't built an HCP commentary report on NCT02113982 (tagraxofusp in blastic plasmacytoid dendritic cell neoplasm or AML) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02113982 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Acute Myeloid Leukemia (AML)
- Interventions
- Tagraxofusp
- Arms
- First-Line Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) · Experimental
- Relapse/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) · Experimental
- Acute Myeloid Leukemia · Experimental
- Enrollment
- 138
- Primary outcomes
- MTD (Stage 1)
- CR Rate in First-line BPDCN (Stage 3, Pivotal Cohort)
- Sponsor
- Stemline Therapeutics, Inc. with The Leukemia and Lymphoma Society
- Start
- Sep 2014
- Primary completion
- Feb 1, 2020
- Results posted
- Yes
- Registry record
- NCT02113982 · updated Aug 1, 2024
Publications
linked from the registry- Konopleva M, Pemmaraju N, Sweet KL, Stein AS, Rizzieri DA, Wang ES, Vasu S, Rosenblat T, Zuurman M, Gupta I, Lane AA. Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm. Cancer. 2026 Jan 1;132(1):e70243. doi: 10.1002/cncr.70243. PubMed 41486505
- Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 Sep 10;40(26):3032-3036. doi: 10.1200/JCO.22.00034. Epub 2022 Jul 12. PubMed 35820082
- Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. doi: 10.1056/NEJMoa1815105. PubMed 31018069